| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000044803 |
| Receipt No. | R000051168 |
| Scientific Title | Study on the effects of research food intake on fatigue, sleep, and concentration. |
| Date of disclosure of the study information | 2021/07/11 |
| Last modified on | 2022/01/06 (Ver. 3) |
| Basic information | ||
| Public title | Study on the effects of research food intake on fatigue, sleep, and concentration. | |
| Acronym | Study on the effects of research food intake on fatigue, sleep, and concentration. | |
| Scientific Title | Study on the effects of research food intake on fatigue, sleep, and concentration. | |
| Scientific Title:Acronym | Study on the effects of research food intake on fatigue, sleep, and concentration. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult (worker) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the effects of QOL Bacillus subtilis subsp. natto-containing food on fatigue, sleep, and concentration after 8 weeks of continuous intake, using placebo as a control. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | (1) Athens Insomnia Scale
(2) The Japanese version of the Pittsburgh Sleep Quality Index (3) OSA sleep inventory MA version Evaluate before ingestion and 4 to 8 weeks after ingestion. |
| Key secondary outcomes | (1) Salivary s-IgA secretion rate
(2) Stress markers in the blood (DHEA-S, Cortisol) (3) POMS2 shortened version for adults (4) Fatigue VAS (5) Fatigue accumulation self-diagnosis checklist (6) Uchida-Kraepelin test (7) Purdue Pegboard Test Evaluate before ingestion and 4 to 8 weeks after ingestion. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | 2 grains of the test product daily oral intake for 8 weeks. | |
| Interventions/Control_2 | 2 grains of the placebo daily oral intake for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Healthy worker between the ages of 20 and 64.
(2) Subjects with a total score of 6 or more on the Pittsburgh questionnaire at the time of pre-examination. |
|||
| Key exclusion criteria | (1) Subjects who routinely use food containing of abundant Bacillus natto, health foods, quasi-drugs, or drugs.
(2) Subjects who act for the purpose of improving sleep, stress, fatigue (including hospital visits and treatment), and use medicines and health foods. (3) Night and day shift worker or manual laborer. (4) Subjects who have a disease that is being treated or who have a disease that is deemed to require treatment. (5) Subjects who are under treatment or have a history of serious diseases (e.g., diabetes, liver disease, kidney disease, or heart disease). (6) Subjects who are a history of mental illness (e.g., depression). (7) Subjects having possibilities for emerging allergy related to the study. (8) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire and other questionnaires. (9) Subjects who cannot carry out the procedures of various tests to be carried out during this study. (10) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination before intake. (11) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study. (12) Subjects who are planned to become pregnant or are pregnant or lactating. (13) Subjects who are judged as unsuitable for the study by the investigator for other reason. |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | IKEDA FOOD RESEARCH CO.,LTD | ||||||
| Division name | Food Science and Technology Institute | ||||||
| Zip code | 721-0956 | ||||||
| Address | 95-7, Minooki-cho, Fukuyama-city, Hiroshima, Japan | ||||||
| TEL | 084-957-3411 | ||||||
| n.nakamura@ikedatohka.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | EP Mediate Co., Ltd. | ||||||
| Division name | Development Business Headquarters, TTC Center, Trial Planning Department | ||||||
| Zip code | 162-0822 | ||||||
| Address | Tsuruya Bldg., 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo | ||||||
| TEL | 03-5657-4983 | ||||||
| Homepage URL | |||||||
| yamamichi.shingo578@eps.co.jp | |||||||
| Sponsor | |
| Institute | EP Mediate Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | IKEDA FOOD RESEARCH CO.,LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Medical Station Clinic Research Ethics Committee |
| Address | 3-12-8, Takaban, Meguroku, Tokyo |
| Tel | 03-6452-2712 |
| saito.teruo876@eps.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051168 |